Activation of platelets by agonists, such as collagen and thrombin, results in shedding of membrane microparticles (MP) 1 from their surface (1). Formation of MP results from an exocytotic budding process (2, 3) and may include both procoagulant (4, 5) and anticoagulant (6, 7) proteins when shed from platelets. Increased circulating concentrations of MP have been detected in vivo in syndromes of platelet activation (8, 9). It is likely that the shear forces in areas of disordered flow would favor MP formation (10, 11).
Activation of platelets by agonists, such as collagen and thrombin, results in shedding of membrane microparticles (MP) 1 from their surface (1) . Formation of MP results from an exocytotic budding process (2, 3) and may include both procoagulant (4, 5) and anticoagulant (6, 7) proteins when shed from platelets. Increased circulating concentrations of MP have been detected in vivo in syndromes of platelet activation (8, 9) . It is likely that the shear forces in areas of disordered flow would favor MP formation (10, 11) .
MP might themselves evoke cellular responses in the immediate microenvironment of their formation. For instance, activation of endothelial cells results in MP shedding, which, in turn, activates neutrophils, enhancing their propensity to adhere to endothelium (12) . Recently, we have demonstrated that arachidonic acid (AA) in platelet MP can influence platelet activation in a PKC-dependent manner and endothelial cell COX-2 expression via transcellular lipid metabolism (13) . The molecular mechanisms by which MP induce such cellular responses are, however, unknown. The present studies were designed to delineate the signaling pathways involved in MPinduced COX-2 activation and prostaglandin formation.
COX is the first rate-limiting enzyme in the synthesis of prostacyclin, prostaglandins, and thromboxane from arachidonic acid (14) . Two isozymes of COX have been described (15, 16) , and both catalyze the cyclooxygenase-dependent transformation of prostaglandin G 2 from AA and the subsequent peroxidation of prostaglandin G 2 to prostaglandin H 2 (17) . While COX-1 is expressed constitutively in most tissues, COX-2 is usually induced as an immediate early gene by mitogenic or inflammatory stimuli as well as by ligands that act via G protein-and PKC-mediated pathways (18) . More recent findings link the prostaglandin biosynthetic pathways with activation of MAPK signaling cascades (19 -21) .
The MAPK pathway, of which there are three subgroups, is a conserved eukaryotic signaling cascade that is responsible for mediating the effects of extracellular stimuli on a wide variety of biological processes. The extracellular signal-regulated kinases (also termed p42 MAPK and p44 MAPK) and the stressactivated protein kinases (also termed c-Jun NH 2 -terminal kinase (JNK)) and p38 (22) are distinguished by activating signals, substrate specificity, and cellular responses (23) . While * This work was supported by National Institutes of Health Grants HL57847 and HL50400 (to G. A. F.) and CA74197 (to M. G. K.) and American Cancer Society Grant RPG-97-092-01-CNE (to M. G. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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the extracellular signal-regulated kinases are predominantly activated by growth factors (24, 25) , the JNKs and p38 MAPKs are activated by stress signals such as inflammatory cytokines, heat shock, ultraviolet light, and ischemia (26) .
It is thought that polyunsaturated fatty acids may influence gene regulation indirectly, via activation of membrane receptors coupled to downstream signaling cascades (27) or perhaps via nuclear receptors (28, 29) . We have previously demonstrated that unmetabolized AA in platelet MP modulates adhesive interactions between monocytes and endothelial cells (30) , a cellular interaction thought to be of relevance in the early stages of atherogenesis (31) . Given that neither a membrane nor a nuclear receptor with high affinity for AA has been identified, we thought it of interest to delineate the molecular mechanisms that underlie this phenomenon.
In the present study, we show that MP AA mimics the effect of MP in inducing COX-2 expression and prostaglandin formation in U-937 cells. MP AA activates PKC, p42/p44 MAPK, p38 kinase, JNK1, c-Jun, and Elk-1. Furthermore, inhibition of PKC, p42/p44 MAPK, p38 kinase, and PI 3-kinase prevents MP-mediated COX-2 expression and prostaglandin formation. These observations suggest that platelet MP AA may activate a membrane-linked signaling cascade that culminates in expression of COX-2 rather than requiring activation of nuclear receptors to regulate gene expression. 32 P]ATP (3000 Ci/mmol) were purchased from Amersham Pharmacia Biotech. Mouse monoclonal antibodies against COX-1 and COX-2 were kindly provided by the late Dr. J. Maclouf (INSERM, Paris, France). The COX-2 promoter construct was a kind gift from Dr. S. Prescott (University of Utah, Salt Lake City, UT). The affinity-purified antibodies against PKC␤, PKC␦, PKC, and PKC were purchased from Transduction laboratories (Lexington, KY). Phosphoplus p42/p44 MAPK, and p38 MAPK antibody kits and the MEK-1 inhibitor 2-(2Ј-amino-3Ј-methoxyphenyl)-oxanaphthalen-4-one (PD98059) were purchased from New England Biolabs (Beverly, MA). Rabbit polyclonal antibody against nonphosphorylated JNK and mouse monoclonal antibody against phosphorylated JNK were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The PathDetect TM in vivo signal transduction pathway transreporting system was purchased from Stratagene (La Jolla, CA). The luciferase assay kit and the pGL2-Basic vector were purchased from Promega (Madison, WI).
MATERIALS AND METHODS

Reagents
Isolation of Platelets, Preparation of Platelet MP, and Their Identification-Platelets were obtained from healthy volunteers as described previously (13) . The volunteers had not taken any medication for at least 14 days. Briefly, blood was collected into a plastic syringe containing 3.8% buffered sodium citrate as anticoagulant (ratio 1:9). Plateletrich plasma was prepared by centrifugation at 130 ϫ g for 15 min, and platelet-poor plasma by centrifugation of platelet-rich plasma at 900 ϫ g. Washed platelets were isolated from platelet-rich plasma after centrifugation and resuspended in calcium-and magnesium-free Hepes buffer (pH 7.4). The platelet number was always adjusted to 3 ϫ 10 8 /ml. Platelet aggregation was studied at 37°C using washed platelets in a PAP-4 model aggregometer (BIO-DATA Corp., Hatboro, PA) in siliconized cuvettes with continuous stirring.
Platelet MP were isolated after platelet aggregation, as described previously (13) . Samples were analyzed on a flow cytometer (FACScan; Becton Dickinson, Mountain View, CA), and each preparation was assayed to exclude endotoxin contamination, using the Limulus amebocyte lysate assay. Final endotoxin contamination was always Ͻ0.02 unit/mg of protein. MP were also preincubated with polymixin B (50 g/ml) for 1 h before their addition to U-937 cells to exclude bacterial contamination.
Cell Culture-U-937 cells, obtained from the American Type Tissue Culture Collection (Rockville, MD), were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 g/ml streptomycin, and 100 units of penicillin. They were washed twice with RPMI 1640, and 5 ϫ 10 5 cells/well were plated into 12-well tissue culture plates. Cell viability was determined by the trypan blue exclusion test. Indomethacin (20 M) was always present in the medium for all experiments described.
Isolation of Arachidonic Acid-AA isolation was performed as described previously (13) . Briefly, lipids were extracted according to a modified version of the method of Bligh and Dyer (32) and separated as described in our previous publication (13) . The free fatty acid fraction was purified by amino (NH 2 ) column chromatography (International Sorbent Technology, Glamorgan, United Kingdom) followed by TLC. The band with the same R f as standard AA was extracted from the TLC plate and purified by reverse phase high performance liquid chromatography. Identification of AA was confirmed by negative ion chemical ionization mass spectrometry, as described previously (13) .
[ Analysis of COX Expression-Western blot analysis of COX proteins was carried out as described previously (13) . Briefly, U-937 cells were stimulated with MP (6 g/ml), the equivalent of 10 M MP AA (3 g/ml) and lysed following stimulation for 2, 6, 12, or 24 h. Equal amounts of protein (20 and 40 g for COX-1 and COX-2, respectively) were separated by 7% SDS-PAGE and transferred to nitrocellulose. After blocking the membranes for 2 h with 5% fat-free milk in Tris-buffered saline (Tris-HCl, pH 7.5, 250 mM NaCl, 0.1% Tween 20), they were incubated with mouse monoclonal antibody directed against either COX-1 or COX-2 at a dilution of 1:10,000 for 1 h at room temperature. Both antibodies are specific for their respective enzymes, as described previously (33, 34) . Membranes were incubated with sheep anti-mouse IgG conjugated with horseradish peroxidase at 1:2000 for 1 h at room temperature. Chemiluminescent substrates were used to reveal positive bands that were visualized after the exposure to Hyperfilm ECL (Amersham Pharmacia Biotech).
Gas Chromatography/Mass Spectrometry-GC/MS analysis studies were performed on a Fisons MD-800 GC/MS (VG Organic, Manchester, UK) equipped with a split/splitless injector operated in the splitless mode at 260°C. The ions monitored were m/z 614 for TxB 2 (35) . The specific enzymatic activities of the PKC isoforms used in this study have been previously described (35) . PKC activity was measured using a mixture of 50 mM Tris-HCl, pH 7.4, 2 mM EGTA, 50 M ATP, [␥-32 P]ATP (3 Ci/tube), 15 mM C 4 H 6 O 4 Mg, 10 M ␣-pseudosubstrate peptide (RFARKGSLRQKNV) as the phosphoacceptor, the corresponding PKC isozyme, and increasing concentrations of AA. No PMA or phosphatidylserine (PS) was added. Assays were carried out at 30°C for 5 min. Results are expressed and normalized as a percentage of the maximum stimulation observed for each PKC isoform. We selected 100 g/ml PS alone as a PKC activator in the case of PKC and 100 g/ml PS and 10 M PMA for all other PKC isozymes (35) .
Analysis of Translocation of PKC Isozymes-U-937 cells were treated with different concentrations of MP or MP AA. Cytosolic and particulate fractions were separated by ultracentrifugation as described by Szallasi et al. (36) , and PKC was evaluated in both fractions by kinase activity or by Western blotting. Total PKC activity in each fraction was measured using the conditions described above but with the addition of PS (100 g/ml) and PMA (10 M) to the mixture for maximal stimulation. For Western blot analysis, samples of the cytosolic and particulate fractions were subjected to immunoblot analysis using specific antibodies for each PKC isozyme. Briefly, after incubation with MP or MP AA, U-937 cells were lysed in ice-cold buffer containing 20 mM Tris-HCl, pH 8.0, 1 mM EDTA, 5 g/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride, 1 g/ml leupeptin, and 10 g/ml aprotinin. The cell lysate was centri-fuged at 14,000 ϫ g for 2 min. The protein content was determined using a microbicinchoninic acid assay (Pierce) with bovine serum albumin as the standard. Equal amounts of protein for each fraction (20 g) were subjected to 10% SDS-PAGE and transferred to nitrocellulose membranes. Membranes were then blocked for 2 h with 5% fat-free milk in Tris-buffered saline and incubated with specific antibodies for PKC␤, -␦, -, or -, according to the manufacturer's instructions (Transduction Laboratories). Membranes were then incubated with sheep anti-mouse IgG for PKC␤ and PKC and sheep anti-rabbit IgG for PKC␦ and PKC, conjugated with horseradish peroxidase, at a 1:5000 dilution for 1 h at room temperature. Bands were resolved using chemiluminescence (ECL, Amersham Pharmacia Biotech). Densitometric analysis of the bands in the Western blot was performed with a Scanner Control, version 1.00 (Molecular Dynamics, Inc., Sunnyvale, CA).
Analysis of Expression of p42/p44 MAPK, p38 MAPK, and JNK-U-937 cells were cultured for 24 h in RPMI 1640 medium containing antibiotics and 0.5% heat-inactivated fetal calf serum, and then treated with MP (30 g/ml) or MP AA (30 M) for various times. After incubation, cells were lysed in ice-cold lysis buffer containing 20 mM Tris-HCl, pH 8.0, 1 mM EDTA, 5 g/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride, 1 g/ml leupeptin, 10 g/ml aprotinin, 10 mM sodium fluoride, and 25 mM sodium pyrophosphate. The cell lysate was centrifuged at 14,000 ϫ g for 2 min. The supernatant was used for immunoblotting with specific antibodies for the phosphorylated or total p42/p44 MAPK, p38 or JNK1/2, using the experimental conditions described by the manufacturer (New England Biolabs). Bands were resolved by chemiluminescence as described above.
Determination of MP-induced COX-2, c-Jun, Elk-1, and CRE Transcriptional Activation-To investigate MP-induced COX-2 transcriptional activation, we employed a construct containing a 2.0-kilobase pair fragment of the promoter region of human COX-2, EcoRI (Ϫ1840) to MspA1I (ϩ123) (5 base pairs upstream of ATG), which was cloned into the HindIII site upstream of the Photinus pyralis (firefly) luciferase gene in the pGL2-Basic vector (Promega) after linker ligation. This COX-2 construct has been previously described in more detail (37) . We employed two methods to investigate MP-induced CRE activation. First, we generated a truncated form of the COX-2 promoter from Ϫ87 to ϩ123 by polymerase chain reaction. This fragment contains the previously identified CRE site (TTCGTCA) (38) . We subcloned it into the HindIII site and the BglII site of the pGL2-Basic vector. Second, we employed the PathDetect cis-reporting system (Stratagene, La Jolla, CA), which includes a reporter plasmid containing the luciferase reporter gene driven by a basic promoter element (TATA box) plus tandem repeats of the CRE. The pFC-PKA plasmid driven by a cytomegalovirus promoter and containing the PKA catalytic subunit was used as a positive control to monitor the activity of CRE. We also employed the PathDetect trans-reporting system to investigate MP-induced transcription factor activation. This includes a pathway-specific fusion trans-activator plasmid, which is an in-frame fusion of an activation domain and the DNA binding domain of the yeast trans-activator GAL4. A GAL4-c-Jun-(1-223) plasmid controlled by an SV40 promoter or a GAL4-c-Elk-1-(307-427) plasmid controlled by an MLV promoter fusion protein were employed for these experiments. MEKK-(380 -672) and MEK1 (S218/222E,⌬32-51) plasmids were used as positive controls to monitor the activity of c-Jun and Elk-1 respectively. The pFR-Luc reporter plasmid contains a synthetic promoter with five tandem repeats of the yeast GAL4 upstream activating sequences that control expression of the firefly luciferase gene. All experiments involving the COX-2 promoter or a truncated form of the promoter, employed the pGL2-Basic vector (Promega), which lacks the COX-2 promoter, as a negative control. The pFC-dbd plasmid (Stratagene, La Jolla, CA), which lacks the activation domain of either c-Jun, Elk-1, or CRE but contains a GAL4-dbd-(1-147) domain and is controlled by an SV40 promoter, was used as a negative control for the trans-and cis-reporting systems, respectively. Forskolin (10 M) was used as a positive stimulus to monitor the activation of both the COX-2/CRE sequence and the CRE cis-reporting system. U-937 cells (6 ϫ 10 6 ) were cultured for 24 h in RPMI 1640 containing antibiotics and 0.5% heat-inactivated fetal calf serum, following transfection with the COX-2 promoter to avoid serum induction of COX-2. Cells were also transfected with the truncated form of the COX-2 promoter containing the CRE sequence or with the pGL2-Basic vector as a negative control. Transfections were performed using Super-FECT TM (Qiagen, Valencia, CA) according to the manufacturer's instructions. Similarly, cells were cotransfected with luciferase reporter plasmids along with various amounts of c-Jun or Elk-1 expression plasmids or the pFC-dbd plasmid as a negative control. Cells were also transfected with the CRE expression plasmid alone or the pFC-dbd plasmid. Cells were then treated with either MP (30 g/ml), MP AA (30 M), or forskolin (10 M) for the indicated time periods. Following stimulation, cells were collected, washed with PBS, and lysed in lysis buffer (Promega). The lysate was centrifuged at 14,000 ϫ g for 2 min, and the supernatant was then assayed for luciferase activity, using a commercial assay kit (Promega). Luminescence was recorded at 560 nm using a Monolight 2010 luminometer (Analytical Luminescence Laboratory). The protein concentration was determined (Pierce) and used for normalization of the luciferase assays.
Statistical Analysis-Results are expressed as mean Ϯ S.E. Statistical comparisons were made by using analysis of variance with subsequent application of Student's t test, as appropriate.
RESULTS
Induction of Cyclooxygenase Activity by Platelet MP-Treatment of U-937 cells with MP induced the expression of COX-2, which was maximal at 12 h (Fig. 1A) . No changes in the expression of COX-1 were observed after MP treatment (Fig.  1E) . Expression of COX-2 protein coincided with an increase in PGE 2 and TxB 2 synthesis, as measured in the supernatant (Table I ). This increase was dose-dependent (data not shown). The EC 50 values were 3 and 6 g/ml of MP protein for PGE 2 and TxB 2 , respectively. Indomethacin (20 M), which is a preferential inhibitor of COX-1, which is expressed constitutively in U-937 cells, was always present in the medium (39) . Actinomycin D (12 M) and cycloheximide (5 g/ml), two inhibitors of protein synthesis, prevented MP-induced COX-2 expression (Fig. 1A) as well as production of PGE 2 and TxB 2 (Table III) . L-745,337 (10 M), a highly specific inhibitor of COX-2 activity (40), markedly reduced the ability of MP to augment PGE 2 and TxB 2 production (Table I) .
MP AA Mimics the Effect of MP on COX-2 Expression-
The fatty acid fraction isolated from MP was found to account for the increase in expression of COX-2. AA isolated from this fraction was found to mimic the kinetics of the COX-2 expression induced by intact MP (Fig. 1C) . No changes in COX-1 expression were observed (Fig. 1E) . To address further the likelihood that MP-dependent induction of COX-2 was mediated by AA itself and not by its prostaglandin metabolites, we co-incubated U-937 cells with a stable prostacyclin analogue, Iloprost (100 nM), with U46619 (1 M), and with PGE 2 (10 M). Although all three were found to induce COX-2 expression in U-937 cells, the kinetics of protein expression were substantially different from those evoked by MP. Maximum induction of COX-2 expression by both U46619 and PGE 2 occurred at 6 h, while Iloprost-induced COX-2 was maximal at 24 h (data not shown). The time course of COX-2 induction by AA, by contrast, corresponded to that evoked by platelet MP (Fig. 1C) .
Since we have previously shown that MP donate AA for transcellular metabolism in endothelial cells (13) (Table II) . Thus, MP AA may be used as a substrate for prostaglandin formation by MP-induced COX-2 in U-937 cells.
PKC, p42/p44 MAPK, p38 Kinase, and PI 3-Kinase Mediate MP-induced COX-2 Expression-To address the possible involvement of PKC in MP-induced U-937 COX-2 and prostaglandin formation, cells were pretreated with GF 109203X (5 M), a PKC inhibitor (41) . GF 109203X abolished the MP and the MP AA effect on COX-2 expression, while the PKA inhibitor H-89 (10 M) was without effect (Fig. 1, A and C) . However, since GF 109203X does not inhibit either PKC or PKC, they are unlikely to be involved in MP-induced COX-2 expression. GF 109203X also inhibited the synthesis of PGE 2 and TxB 2 induced by MP, while H-89 was again ineffective (Table III) . Cells were incubated with PD98059 (10 M) and SB203580 (10 M), inhibitors of MEK1 (42) and p38 kinase (43), respectively, as a first approach to investigate whether the MAPK cascade could play a potential role in MP-and MP AA-induced COX-2 expression and prostaglandin formation. Pretreatment with each of these inhibitors resulted in down-regulation of MP and MP AA-induced COX-2 expression (Fig. 1, B and D) and prostaglandin formation (Table III) . Likewise, pretreatment of U-937 cells with the PI 3-kinase inhibitors LY2094002 (20 M) and wortmannin (100 nM) (44) abolished the expression of COX-2 induced by either MP (Fig. 1B) and MP AA (Fig. 1D) as well as prostaglandin formation (Table III) .
MP Induce PKC Isozyme Activation-The observation that GF 109203X prevented MP-and MP AA-induced COX-2 and prostaglandin formation suggested that MP treatment may lead to PKC activation. We examined the effect of MP on the translocation of PKC isozymes from cytosolic to particulate fractions to address further this hypothesis (45) (46) (47) . Platelet MP markedly alter the distribution of PKC, as judged by the evaluation of kinase activity in subcellular fractions. Most of the PKC activity (approximately 70%) was present in the cytosolic fraction in unstimulated U-937 cells, as previously observed in fibroblasts and keratinocytes (33, 43) . Treatment of U-937 cells with MP leads to a dose-dependent reduction in the cytosolic PKC activity, with a concomitant increase in activity in the particulate fraction. Total PKC activity in the cytosolic fraction was reduced by 72 Ϯ 3% (n ϭ 3) at the highest concentration of MP tested (100 g/ml) ( Fig. 2A) .
Since PKC comprises a family of at least 11 isoforms with differences in regulation and subcellular distribution, we evaluated the translocation of individual PKC isozymes by Western blot analysis. While previous studies have identified PKC␤, PKC⑀, and PKC isozymes in U-937 cells (48), we found that they also express PKC␦ and PKC. Very low levels of PKC⑀ were also detected (data not shown). PKC␤ (a classical or calcium-dependent PKC), PKC ␦ (a novel or calcium-independent PKC), and PKC and PKC (atypical or phorbol ester/ diacylglycerol-insensitive PKCs), translocate from the soluble to the particulate fraction upon MP stimulation in a concen- 
formation by U-937 cells stimulated with platelet MP in the presence or absence of the COX-2 inhibitor L-745,337
Time course analysis of prostanoid production by U-937 cells stimulated with platelet MP (6 g/ml) in the presence or absence of L-745,337 (10 M). The supernatant was assayed for PGE 2 (Fig. 3A) . No changes were observed in the content of total PKC isozymes in total lysates. Densitometric analysis of the bands revealed a loss of 94 Ϯ 4%, 75 Ϯ 3%, 70 Ϯ 6%, and 92 Ϯ 2% (n ϭ 4) for cytosolic PKC␤, PKC␦, PKC, and PKC, respectively, at the highest concentration (100 g/ml) of MP tested (Fig. 3B) . Therefore, translocation of U-937 cell PKC isozymes by platelet MP does not appear to discriminate among the different PKC subtypes present in the cell.
We studied the phosphorylation of PKC substrates to investigate further MP-induced PKC activation. Phosphorylation in intact cells has also been employed as an index of PKC activation. It was previously reported that treatment of monocytes and U-937 cells with PKC activators increases the phosphorylation of substrates of 120, 85, and 28 kDa (49, 50). There was a marked increase in the phosphorylation state of each of the three substrates by 312 Ϯ 15, 441 Ϯ 21, and 185 Ϯ 30% (n ϭ 4), respectively, in U-937 cells radiolabeled with [ 32 P]orthophosphate, 10 min after stimulation with MP (30 g/ml) (data not shown). Similar phosphorylation was observed when the cells were treated with PMA (100 nM) for 10 min. The phosphorylation observed after MP or PMA treatment was prevented by pretreatment with the PKC inhibitor GF 109203X (5 M) but not by the PKA inhibitor H-89 (10 M) (data not shown).
MP AA Mimics the Effect of MP on PKC Activation-Micromolar concentrations of AA and other unsaturated fatty acids can directly activate PKC, at least in vitro (51) . We have previously shown that MP AA mediates PKC-dependent platelet aggregation (13) . We treated U-937 cells with AA purified from MP, fractionated the cells by ultracentrifugation, and measured total PKC activity in the soluble (cytosolic) and particulate fractions. AA (100 M) induced the redistribution of PKC activity from cytosolic to the particulate fractions, as observed for intact MP. Western blot analysis revealed that AA (100 M) translocated all of the PKC isozymes present in U-937 cells from the cytosolic to the particulate fraction (Fig. 4A) . Densitometric analysis of the bands revealed a loss of immunoreactivity from the cytosolic fractions of 75 Ϯ 9, 57 Ϯ 2, 50 Ϯ 5, and 82 Ϯ 8% for PKC␤, PKC␦, PKC, and PKC, respectively (Fig.  4B) . No changes in PKC activity were observed in aliquots of total lysates.
The effect of MP AA on PKC activation observed in U-937 cells was corroborated by in vitro kinase assays using recombinant PKC isozymes expressed in and purified from Sf9 insect 
of MP-stimulated prostanoid formation by U-937 cells on PKC, MAPK, p38, PI 3-kinase, and de novo protein synthesis
U-937 cells were incubated with cycloheximide (CHX) (5 g/ml) for 1 h before the addition of MP. Cells were co-incubated with actinomycin D (ACT) (12 M) and platelet MP (6 g/ml). GF 109203X (GF) (5 M), H89 dihydrochloride (H89) (10 M), PD98059 (PD) (10 M), SB203580 (SB) (10 M), LY294002 (LY) (20 M), or wortmannin (Wort) (100 nM) were added to the cells for 1 h before the addition of platelet MP. TxB 2 and PGE 2 production were measured in the supernatant by GC/MS after a 12-h incubation period. Each value represents the mean Ϯ S. cells/ml) were stimulated with MP (1-100 g/ml) (A) or MP AA (100 M) (B) for 10 min. Kinase assays were carried out at 30°C for 5 min. Cells were fractionated by ultracentrifugation for 1 h at 100,000 ϫ g, and samples were assayed for PKC activity as described under "Materials and Methods." Results are expressed as mean Ϯ S.E. from three independent experiments. cells (35) . AA was capable of stimulating PKC␤, -␦, and -in a concentration-dependent fashion (Table IV) . We did not study MP AA activation of PKC, since the purified enzyme was not available. A similar pattern of activation was observed with other PKC enzymes, such as PKC␣, which are not present in U-937 cells (data not shown). In vitro assays, using U-937 cells as a source of PKC, also revealed that MP AA induces activation of total PKC in U-937 cells (Table IV) . Similar results in U-937 cells and in in vitro kinase assays were observed with AA obtained from a commercial source (Sigma) (data not shown). The PKC inhibitor, GF 109203X (5 M), totally abolished MPinduced activation of U-937 PKC and recombinant PKC␤ and PKC␦. PKC is insensitive to PKC inhibitors known to interfere with the catalytic domain of this enzyme (Ref. 41 , and data not shown).
MP Induce Activation of p42 and p44 MAPK-Since PD98059, a specific inhibitor of MEK (42), prevented MP and MP AA-induced COX-2 activation (Fig. 1, B and D) , we turned our attention to the MAPK signaling cascade. We studied the phosphorylation of MAPK in cell lysates to determine whether MP-induced activation of COX-2 was consistent with upstream activation of MAPK. We evaluated the phosphorylation of MAPK using phosphospecific antibodies as an index of MAPK activation (52-54). Phosphorylation of both p42 and p44 MAPK by MP (30 g/ml) was evident as early as 5 min; this declined by 30 min and returned to basal levels at 1 h (Fig. 5B) . Total 5 cells/ml) were treated with MP (1-100 g/ml) for 10 min and then fractionated into cytosolic or particulate fractions as described under "Materials and Methods." Equal amounts of protein were subjected to 10% SDS-PAGE and analyzed by Western blotting using antibodies raised against PKC␤, PKC␦, PKC, and PKC (A). B, quantitation of immunoblots by densitometric analysis. The figure is representative of four separate blots, and the densitometry values are expressed as mean Ϯ S.E. from four independent experiments.
MAPK levels were not changed, as judged with a MAPK antibody that recognized both the phosphorylated and unphosphorylated forms of the enzyme (Fig. 5A) .
We addressed the hypothesis that PKC influenced MP-induced phosphorylation of both p42 and p44 MAPK by pretreating the cells with GF 109203X (5 M) for 1 h prior to stimulation. GF 109203X completely inhibited MP-induced phosphorylation of p42 and p44 MAPK (Fig. 5B) . Likewise, staurosporine (100 nM), a nonspecific PKC inhibitor, also inhibited MPinduced p42/p44 MAPK phosphorylation (data not shown). Again, it seems likely that PKC and PKC are not involved, since neither is inhibited by GF 109203X. Pretreatment of the cells with PMA for 48 h down-regulated PKC (55) and also totally inhibited the activation of p42/p44 MAPK by FIG. 4 . MP AA translocates PKC isozymes. U-937 cells (5 ϫ 10 5 cells/ml) were treated with MP AA (100 M) for 10 min and then fractionated into cytosolic or particulate fractions as described under "Materials and Methods." Equal amounts of protein were subjected to 10% SDS-PAGE and analyzed by Western blotting using antibodies raised against PKC␤, PKC␦, PKC, and PKC (A). Quantitation of immunoblots was by densitometric analysis (B). The figure is representative of four separate blots, and the densitometry values are expressed as mean Ϯ S.E. from four separate experiments.
TABLE IV MP AA stimulates PKC in vitro
Increasing concentrations of MP AA (3-100 M) were added to a mix containing U-937 total lysate as the source of PKC. Alternatively, MP AA (3-100 M) was added to a mix containing recombinant PKC␤, PKC␦, or PKC isozymes purified from Sf9 insect cells and assayed. GF 109203X was used at a concentration of 5 M. Kinase assays were carried out at 30°C for 5 min, and results are expressed and normalized as percentage of maximal PKC activation when using as PKC activators 100 g/ml PS alone for PKC and 100 g/ml PS and 10 M PMA for all other isozymes. Results are expressed as mean Ϯ S.E. of four independent experiments. MP (Fig. 5B) . Pretreatment of the cells for 1 h with PD98059 (10 M), an inhibitor of MEK1 (42), was also found to abolish completely MP-induced p42/p44 MAPK activation (Fig. 5B) . To investigate whether PI 3-kinase is upstream or downstream of PKC in our system, we pretreated cells with LY294002 before stimulation with PMA. LY294002 failed to inhibit PMA-induced p44/p42 MAPK phosphorylation, indicating that PI 3-kinase resides upstream of PKC (Fig. 5D) . MP Induce Activation of p38 Kinase and JNK-SB203580, a specific inhibitor for p38 activation (43), suppressed MP-and MP AA-induced COX-2 activation (Fig. 1, B and D) . This result suggests that more than one MAPK cascade could be activated by MP treatment. Therefore, we evaluated the activation of p38 and JNK, using a similar approach as that used for p42/p44 MAPK. MP induced the phosphorylation of p38 (Fig. 6B) . Activation of p38 was transient, similar to MP-induced p42/p44 MAPK activation. Maximal phosphorylation was observed at 5 min, which returned to near basal levels by 1 h post-MP treatment. Unlike MP-induced p42/p44 activation, however, MPinduced p38 phosphorylation is PKC-independent, since GF 109203X (5 M) was without effect (Fig. 6B) . Likewise, staurosporine (100 nM), was ineffective in preventing MP-induced p38 MAPK activation (data not shown). Pretreatment of the cells with SB203580 (10 M) had no effect on MP-induced phosphorylation of p38 (Fig. 6B) as described previously by Cuenda et al. (43) . Similarly, the MEK1 inhibitor PD98059 (10 M), failed, as expected, to inhibit MP-induced p38 phosphorylation (data not shown). Total p38 protein levels were not changed by the MP treatment (Fig. 6A) .
MP also induced the phosphorylation of JNK. The dominant form of JNK in U-937 cells is the 46-kDa form or JNK1 (Fig.  7A) as previously reported (56) . When U-937 cells were treated with MP (30 g/ml), the level of phosphorylated JNK1 was significantly elevated within 5 min and remained so for 9 h (Fig. 7B) . Pretreatment of the cells with GF 109203X (5 M) did not inhibit MP-induced activation of JNK1 (Fig. 7B) . A similar effect was observed with staurosporine (100 nM) (data not shown). No pharmacological inhibitors of the JNK pathway are available to our knowledge.
Inhibition of PI 3-kinase activity prevented MP and MP AA-induced COX-2 activation (Fig. 1, B and D) . To determine whether PI 3-kinase activation is relevant to MP-induced p42/ p44 MAPK, p38, and JNK activation, we used the same two pharmacological inhibitors, wortmannin and LY294002 (44) . (Fig. 7C) . Pharmacological inhibition of PKC, MEK1, p38 MAPK, and PI 3-kinase had similar effects with MP AA as observed for intact MP, albeit the effects of inhibition of PI 3-kinase on p38 MAPK were somewhat less pronounced in the case of MP AA (Figs. 5C, 6C, and 7C) .
MP and MP AA Induce Transcriptional Activation of COX-2, c-Jun, and Elk-1 but Not CRE-We investigated whether MP might influence gene regulation to evaluate further their effects on transcriptional activation of the COX-2 gene. When transfected U-937 cells were stimulated with MP (30 g/ml), COX-2 activity increased significantly (Fig. 8) . This was evident as early as 30 min and peaked at 4 h. A similar pattern of activation was observed when cells were stimulated with MP AA (30 M) (Fig. 8) . U-937 cells transfected with the pGL2-Basic vector, which lacks the promoter region of COX-2, showed little or no luciferase activity (Fig. 8) . Furthermore, we also investigated whether MP could induce c-Jun or Elk-1 transcriptional activation. The COX-2 promoter has a CRE to which c-Jun binds (57) . Our observations suggested that Elk-1, a substrate for both extracellular signal-regulated kinases and JNKs, might also regulate COX-2 expression (58, 59) . Both MP and MP AA induction of c-Jun and Elk-1 was maximal at 4 h, similar to the kinetics of transcriptional activation of COX-2 by MP or MP AA (Fig. 8) . U-937 cells cotransfected with the pFR-Luc reporter plasmid and the pFC-dbd plasmid showed little or no luciferase activity (Fig. 8) . Both MP and MP AA induced the transcriptional activation of both c-Jun and Elk-1 as expected. A cross-talk mechanism has been previously reported between the MAPK and JNK signal transduction pathways in U-937 cells (60) . We analyzed MP-and MP AA-induced activation of CRE (which is specifically activated by cAMP) by two methods to test the specificity of our system. In both cases, we failed to see an increase in luciferase activity, while forskolin, which increases cAMP levels, induced maximal CRE activation at 14 h in both systems (Fig. 8) . This is consistent with our earlier results with the PKA inhibitor H-89, which failed to inhibit both MP-and MP AA-induced COX-2 expression (Fig.  1) . Thus, MP-and MP AA-induced transcriptional activation is selective, but the increase in c-Jun activation may not be related to COX-2 induction in our system. Activation of p42/p44 MAPK, p38, JNK phosphorylation, and CRE as well as transcriptional activation of c-Jun, Elk-1, or COX-2 by MP AA was not altered by indomethacin (20 M), a nonspecific inhibitor of COX isoforms. Thus, AA, rather than its COX metabolites, predominantly mediates the effects of the lipid fraction of platelet MP on COX-2 transcription. DISCUSSION MP shed from activated platelets have been shown to influence cellular function. They circulate in syndromes of platelet activation (61) and may accumulate in areas of disordered blood flow (11) . Recently, we have demonstrated that plateletderived MP may facilitate transcellular delivery of AA, thereby modulating aspects of vascular and platelet function (13) . The mechanisms by which MP activate cells remain poorly defined. Platelet MP influence adhesive interactions between monocytes and endothelial cells (30) , a mechanism of potential relevance to initiation of vascular injury at sites of disordered laminar blood flow in the early stages of atherogenesis (31) .
We have previously shown that MP induce human umbilical vein endothelial cell expression of COX-2 (13) . Similarly, we now demonstrate that platelet MP and MP AA induce COX-2 and prostaglandin formation in U-937 monocytoid cells. The signaling pathways that regulate COX-2 expression are incompletely understood but may differ for the same agonist between cells and between agonists with a single cell type (62) (63) (64) . It is unknown how AA regulates COX-2 expression. Indeed, since membrane receptors for AA remain to be identified, it is possible that it may ligate directly nuclear receptors that would regulate gene transcription. We now demonstrate that MP AA activates PKC isozymes as well as all three subgroups of the MAPK cascade. These events culminate in activation of transcription factors of relevance to expression of COX-2.
MP and MP AA induce PKC isozyme phosphorylation and translocation as well as direct activation in vitro. Nishizuka and co-workers have previously demonstrated that micromolar concentrations of AA can activate classical, calcium-dependent PKCs (65) . Given that both MP AA and MP induce an elevation in intracellular calcium in U-937 cells (data not shown) and that calcium has previously been shown to enhance AA-induced activation of PKC (65) , it may be that classical PKCs are the predominant contributors to PKC-dependent effects of platelet MP. However, our findings clearly demonstrate that MP AA also activate novel and atypical PKC isoforms in U-937 cells.
In more recent years, a role for AA in the regulation of MAPK activation as well as transcriptional activation of c-Jun and Elk-1 has been proposed (66 -68) . The kinetics of MP AAinduced p42/p44 MAPK activation are consistent with previous reports on AA-induced p42/p44 MAPK activation in vitro (67) . Particularly notable was the prolonged activation of JNK1 by MP AA and intact MP. Sustained activation of JNK has been described in response to some (69) but not all (70) stimuli.
Induction of COX-2 expression and prostaglandin formation has previously been associated with activation of the MAPK pathway. For example, Xie et al. provided evidence for the role of JNK and c-Jun in mediating v-Src-induced COX-2 gene expression (19) . Similarly, p38 kinase has been implicated in interleukin-1-stimulated COX-2-dependent prostaglandin production in fibroblasts, human umbilical vein endothelial cells, and mesangial cells (20, 21) . Other elements of the prostaglandin pathway have also been linked with activation of MAPKs. For example, both MAPK and p38 mediate biosynthetic activation of cytosolic phospholipase A 2 (71, 72) .
We have demonstrated that MP AA can activate three distinct MAPKs (p42/p44 MAPK, p38, and JNK) in monocytoid cells. Inhibitors of PI 3-kinase inhibit activation of all three kinases by MP AA, whereas inhibitors of PKC inhibit activation of p42/p44 MAPK but not p38 or JNK. The mechanisms involved in MP and MP AA activation of PI 3-kinase are under current investigation. Given that PKC inhibition markedly reduces MP-induced COX-2-dependent prostanoid formation, it would seem that the p38 and JNK cascades play a less important role in this consequence of U-937 cell activation by platelet MP. We also demonstrate that both MP and MP AA can dramatically induce the transcriptional activation of the COX-2 gene. However, since MP and MP AA both failed to induce CRE activation, c-Jun, despite its activation by both MP and MP AA, is unlikely to influence COX-2 transcription in our system. The role of Elk-1 remains to be determined. Although we have focused on MP AA, we do not exclude the possibility of a role for other constituents of the fatty acid fraction in MP that may be of relevance to the regulation of COX-2. A preliminary model of events stimulated by platelet MP is provided in Fig. 9 .
The present observations may also have relevance to the role of platelet activation in atherogenesis. Thus, laminar shear has been shown to produce prolonged up-regulation of COX-2 in endothelial cells (73) . Production of prostacyclin, the predominant COX-2 product in these cells, inhibits platelet activation and adhesive interactions between circulating blood cells and the endothelium (74) . Turbulent shear, by contrast, fails to up-regulate COX-2 in endothelial cells. A similar discrepancy of effect is observed with induction of endothelial nitric-oxide synthase (73) . Given that turbulence may mimic the disordered laminar shear that occurs in vivo at sites of lesion development, this raises the possibility that a localized deficiency in prostacyclin and NO may be of functional relevance to the focal nature of atherogenesis. Thus, disordered shear forces favor platelet activation and the shedding of MP, an effect that can only be amplified by a localized, coexistent deficiency of endogenous platelet inhibitors, such as prostacyclin and NO. We have shown that MP AA can stimulate directly platelet aggregation and adhesive interactions involving both platelets and monocytes with endothelial cells. Furthermore, while disordered shear may impair the ability of endothelial cells to generate COX-2-dependent prostacyclin, stimulation of monocyte and platelet TxA 2 by platelet MP would amplify further platelet activation and the adhesive interactions induced by MP AA. 
